Do GLP-1 medications work as well for Black and Latina women?

Dr. Linda's take

This question comes up in my exam room more than almost any other, and it usually arrives with an apology attached, as though it were impolite to ask. It is not impolite. It is a good clinical question, and it deserves a straight answer built on data rather than on vibes.

So here is the straight answer, up front: where the efficacy has actually been analyzed by race and ethnicity, these medications worked, and no significant difference in treatment effect by race or ethnicity was found. The documented inequity in this field is real, but it is mostly not about whether the medicine works in your body. It is about whether you are offered it in the first place.

Let us walk through what the evidence does and does not show. This is general education, not advice about what any one person should take.

Who is actually carrying the weight of this condition?

Start with the burden, because it frames everything else. According to the National Institute of Diabetes and Digestive and Kidney Diseases, more than half of non-Hispanic Black women, and more than two in five Hispanic women, have obesity, compared with nearly two in five non-Hispanic white women. Those figures come from national survey data collected in 2017 to 2018, so treat them as a picture of that period rather than of this month.

The pattern holds for diabetes as well. Age-adjusted national data from 2019 to 2021 showed that diagnosed diabetes was more common among non-Hispanic Black adults and adults of Hispanic origin than among non-Hispanic white adults.

So the conditions these medications treat fall hardest on exactly the women who most often ask me whether the medications were built with them in mind.

Were women like me even in the trials?

This is the part worth being honest about, because the answer is: not many.

In SURMOUNT-1, the pivotal tirzepatide trial, the prescribing information reports that 71% of participants were White, 11% were Asian, 9% were American Indian or Alaska Native, and 8% were Black or African American, with 48% reporting Hispanic or Latino ethnicity. For semaglutide, the pooled adult weight-reduction trials described in the Wegovy label included 9% Black or African American participants and 13% who reported Hispanic or Latino ethnicity.

A published analysis of the STEP trials puts the same picture in sharper focus: in STEP 1 and STEP 3, participants were 75.3% White and 8.8% Black.

Two cautions on those numbers, because precision matters here. None of these sources break participants out by sex and race together, so "8% were Black women" is not something the data support, and I will not say it. And SURMOUNT-1's high Hispanic or Latino share reflects a multinational trial with substantial Latin American enrollment, which is not the same thing as US Latina representation.

The honest summary is that Black women in particular were a small minority of the participants in the trials that brought these drugs to market.

Do the medications work as well for Black and Latina women?

Here is where a lot of content on the internet goes wrong in one direction or the other, either inventing a disparity that the data do not show or waving away the question entirely.

The best available evidence is a post hoc analysis of three randomized semaglutide trials, published in Obesity in 2024, that specifically examined efficacy and safety by race and ethnicity. It found no significant interactions between treatment effect and race, and concluded that the treatment effect of semaglutide was statistically significant versus placebo and clinically relevant across all racial and ethnic subgroups studied.

That is a genuinely reassuring finding, and I want to state its limits just as clearly. "No significant interaction" is not the same as "proven identical." The Black subgroup was around 9% of participants, which is small, and a small subgroup has limited power to detect a modest difference if one exists. This was also a post hoc analysis rather than the question the trials were designed to answer.

For tirzepatide, we found no published race-stratified efficacy analysis at all. So for that medication, the honest answer is that the evidence does not support a firm conclusion either way.

There is one more thing the labels tell us. Both the Wegovy and Zepbound prescribing information state that race does not have a clinically relevant effect on how the drug moves through the body. Neither label carries a race-based dose adjustment. That is a statement about drug exposure rather than about how much weight a given group loses, but it is a meaningful piece of the picture.

So where is the real disparity?

Not in the pharmacology. In the prescription pad.

A retrospective cohort study of more than one million commercially insured US adults with type 2 diabetes found that Black, Asian, Hispanic and low-income patients were less likely to receive treatment with a GLP-1 receptor agonist than white patients, after adjustment. That study looked at patients with type 2 diabetes rather than at the newer obesity indications, and it predates the current generation of weight-management drugs, so it is a signal rather than the final word.

But it is a signal pointing the same direction as everything women tell me in clinic: the barrier is usually the conversation that never happened, the referral that was never made, the symptom that was attributed to willpower. We wrote about that access gap in more depth in our deeper look at obesity, women of color, and treatment access.

What should you ask your clinician?

If you want a structured way to start that conversation, Body Good Studio's quiz maps your symptoms to a starting point before you speak with a clinician.

Frequently asked questions

Do GLP-1 medications work differently for Black women?

In a post hoc analysis of three randomized semaglutide trials, there were no significant interactions between treatment effect and race, and the treatment effect was clinically relevant across all racial and ethnic subgroups. Because Black participants were a small share of those trials, the analysis has limited power to rule out a modest difference, so this is best read as no evidence of a difference rather than as proof of none.

How many Black and Latina women were in the GLP-1 trials?

Fewer than most people assume. SURMOUNT-1 was 8% Black or African American, and the STEP 1 and STEP 3 trials were 8.8% Black. Importantly, none of the published sources break participants out by sex and race at the same time, so a precise count of Black women or Latina women specifically is not available.

Does race change the dose of a GLP-1?

No. Both the Wegovy and Zepbound labels state that race does not have a clinically relevant effect on the pharmacokinetics of the drug, and neither label includes a race-based dosing adjustment.

If the medication works the same, why do outcomes differ?

The best-documented gap is in access rather than in biology. A large cohort study of insured adults with type 2 diabetes found Black, Asian, Hispanic and low-income patients were less likely to be prescribed a GLP-1 receptor agonist than white patients.

Is there good evidence for tirzepatide specifically in Black and Latina women?

We could not find a published race-stratified efficacy analysis for tirzepatide. That means the honest answer is that the evidence does not currently support a firm conclusion either way, which is different from saying it does not work.

References

1. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (2021). Overweight & Obesity Statistics (NHANES 2017-2018). National Institutes of Health. https://www.niddk.nih.gov/health-information/health-statistics/overweight-obesity (Accessed 2026-07-14).
2. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (2024). Diabetes Statistics. National Institutes of Health. https://www.niddk.nih.gov/health-information/health-statistics/diabetes-statistics (Accessed 2026-07-14).
3. Eli Lilly and Company / U.S. Food and Drug Administration (2026). ZEPBOUND (tirzepatide) injection - Prescribing Information (SURMOUNT-1 baseline demographics, section 14.1). DailyMed, National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b (Accessed 2026-07-14).
4. Novo Nordisk / U.S. Food and Drug Administration (2026). WEGOVY (semaglutide) - Prescribing Information (trial demographics and pharmacokinetics). DailyMed, National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b (Accessed 2026-07-14).
5. Rubino D, Angelene H, Fabricatore A, Ard J, et al. (2024). Efficacy and safety of semaglutide 2.4 mg by race and ethnicity: a post hoc analysis of three randomized controlled trials. Obesity (Silver Spring), via PubMed (National Library of Medicine). https://pubmed.ncbi.nlm.nih.gov/38932728/ (Accessed 2026-07-14).
6. Eberly LA, Yang L, Eneanya ND, et al. (2021). Racial, Ethnic, and Socioeconomic Inequities in Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Diabetes in the US. JAMA Health Forum, via PMC (National Library of Medicine). https://pmc.ncbi.nlm.nih.gov/articles/mid/NIHMS1805081/ (Accessed 2026-07-14).